Kairos Pharma Ltd. (KAPA) carries a Roarable Rating of D (Sell) with 49/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Kairos Pharma Ltd. (NYSE: KAPA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.54 (+3.25% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KAPA ranks #373 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KAPA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MTNB (Matinas Biopharma Holdings Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M) and XRTX (XORTX Therapeutics Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.9M). Among the 5-stock peer group, KAPA leads on earnings multiple (N/A) while KAPA leads on capital efficiency (-35.0% ROIC).
Per KAPA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001962011), Kairos Pharma Ltd. generated $0 in revenue, -$5.4M in net income, and -$3.4M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While KAPA currently carries a cautious 49/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Big institutional funds and options desks are actively positioning on the bullish side.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.33) and Max Pain ($0.57) forces dealer call-delta covering toward $8.09.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Kairos Pharma Ltd. (KAPA) surged +3.25% to $0.54, trading at 2% of its 52-week range ($0.52 – $7.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, C
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KAPA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KAPA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Kairos Pharma Ltd. (KAPA) ranks #373 by composite RQD confidence (49/100, grade D) and #1003 by equity capitalization ($1.8M). Within this direct 5-issuer industry benchmark cohort, KAPA leads on earnings valuation at N/A trailing P/E, while KAPA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PPBT currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with KAPA at 49/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KAPA
ACTIVE
Kairos Pharma Ltd. | D | 49/100 | — | — | -35.0% | +3.25% | $1.8M | Benchmark Subject |
| MTNB Matinas Biopharma Holdings Inc. | D | 45/100 | — | — | -35.0% | -0.52% | $1.9M | /mtnb-vs-kapa → |
| XRTX XORTX Therapeutics Inc. | D+ | 58/100 | — | — | — | -1.90% | $1.9M | /xrtx-vs-kapa → |
| PPBT Purple Biotech Ltd. | C- | 61/100 | — | — | — | +13.86% | $1.8M | /ppbt-vs-kapa → |
| OGEN Oragenics Inc. | D | 44/100 | — | — | -35.0% | -1.53% | $1.7M | /ogen-vs-kapa → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kairos Pharma Ltd. (KAPA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$5.4M, operating cash flow of -$3.4M, and free cash flow of -$3.4M (+13.0% YoY). On the balance sheet, KAPA closed FY2025 with $6.5M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$5.4M | -$3.4M | -$3.4M | $6.5M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$2.6M | -$4.0M | -$4.0M | $5.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$1.8M | $81.0K | $81.0K | — | — |
As of 2026-11-01, Kairos Pharma Ltd. (NYSE: KAPA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 49/100 at a spot price of $0.54 (+3.25% 1D, market cap $1.8M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 15/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, KAPA ranks #373 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KAPA carries a Roarable D (49/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MTNB (Matinas Biopharma Holdings Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M) and XRTX (XORTX Therapeutics Inc.) posts a D+ grade (58/100 RQD, P/E N/A, ROIC —, cap $1.9M). Among the 5-stock peer group, KAPA leads on earnings multiple (N/A) while KAPA leads on capital efficiency (-35.0% ROIC).
Per KAPA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001962011), Kairos Pharma Ltd. generated $0 in revenue, -$5.4M in net income, and -$3.4M in free cash flow against $6.5M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
KAPA last traded at $0.54 (+3.25% on volume of 123,055 shares), positioning the stock -59.40% below its 50-day simple moving average ($1.33) and -82.30% below its 200-day simple moving average ($3.05). Across its 52-week range of $0.52 to $7.70, KAPA sits at the 0.3% percentile with a 14-day RSI of 20.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).
Why KAPA Stock surged +3.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.